

Daniel Weintraub

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7484166/publications.pdf>

Version: 2024-02-01

358
papers

36,876
citations

3151

92
h-index

3822

178
g-index

377
all docs

377
docs citations

377
times ranked

21675
citing authors

#	ARTICLE	IF	CITATIONS
1	Prodromal Dementia With Lewy Bodies: Evolution of Symptoms and Predictors of Dementia Onset. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2022, 35, 527-534.	1.2	19
2	The neuropsychiatry of Parkinson's disease: advances and challenges. <i>Lancet Neurology</i> , The, 2022, 21, 89-102.	4.9	142
3	Validation of the Japanese Version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS). <i>Parkinson's Disease</i> , 2022, 2022, 1-6.	0.6	3
4	Level I α -Synuclein Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 479-483.	0.8	11
5	Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 490-501.	2.2	10
6	Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer's Disease to Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1155-1167.	1.5	9
7	Plasma α -Synuclein, CRP, and Albumin Predict Cognitive Decline in Parkinson's Disease. <i>Annals of Neurology</i> , 2022, 92, 255-269.	2.8	7
8	Quantitative detection of α -Synuclein and Tau oligomers and other aggregates by digital single particle counting. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	13
9	Genetic prediction of impulse control disorders in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 936-949.	1.7	15
10	Non-tremor motor dysfunction in Lewy body dementias is associated with AD biomarkers. <i>Parkinsonism and Related Disorders</i> , 2022, 100, 33-36.	1.1	5
11	Characterization of Non-Motor Fluctuations Using the Movement Disorder Society α -Synuclein Rating Scale. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 932-940.	0.8	5
12	Annual Prevalence of Use of Potentially Inappropriate Medications for Treatment of Affective Disorders in Parkinson's Disease. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 35-47.	0.6	2
13	Differences in the Presentation and Progression of Parkinson's Disease by Sex. <i>Movement Disorders</i> , 2021, 36, 106-117.	2.2	54
14	Prevalence of Non-Motor Symptoms and Non-Motor Fluctuations in Parkinson's Disease Using the α -Synuclein Rating Scale. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 231-239.	0.8	35
15	The Non-Motor Symptoms Scale in Parkinson's disease: Validation and use. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 3-12.	1.0	49
16	Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson's disease. <i>Brain and Behavior</i> , 2021, 11, e02086.	1.0	6
17	Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment. <i>Movement Disorders</i> , 2021, 36, 2549-2558.	2.2	26
18	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. <i>Journal of Parkinson's Disease</i> , 2021, 11, 395-404.	1.5	56

#	ARTICLE	IF	CITATIONS
19	Whole Clinic Research Enrollment in Parkinson's Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 757-765.	1.5	5
20	Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 737-745.	1.5	5
21	Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1972-1978.	2.2	10
22	Movement in Aesthetic Experiences: What We Can Learn from Parkinson Disease. <i>Journal of Cognitive Neuroscience</i> , 2021, 33, 1329-1342.	1.1	2
23	Low continuation of antipsychotic therapy in Parkinson disease – intolerance, ineffectiveness, or inertia?. <i>BMC Neurology</i> , 2021, 21, 240.	0.8	11
24	Trial of Pimavanserin in Dementia-Related Psychosis. <i>New England Journal of Medicine</i> , 2021, 385, 309-319.	13.9	61
25	Parkinson disease-associated cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2021, 7, 47.	18.1	391
26	International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2583-2594.	2.2	54
27	Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson's Disease: A Longitudinal Analysis of Two International Cohorts. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1209-1219.	1.5	29
28	Assessment of Affective-Behavioral States in Parkinson's Disease Patients: Towards a New Screening Tool. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1417-1430.	1.5	1
29	Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. <i>Movement Disorders</i> , 2021, 36, 2945-2950.	2.2	63
30	Predictors of short-term impulsive and compulsive behaviour after subthalamic stimulation in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1313-1318.	0.9	12
31	Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe?. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1181-1188.	0.8	15
32	Dopamine transporter imaging predicts clinically defined α -synucleinopathy in REM sleep behavior disorder. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 201-212.	1.7	37
33	Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias. <i>Neurology</i> , 2021, 96, e1855-e1864.	1.5	28
34	A Model to Assess the Outcomes Associated With Dementia With Lewy Bodies. <i>Alzheimer Disease and Associated Disorders</i> , 2021, 35, 68-74.	0.6	2
35	Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. <i>Neurology: Clinical Practice</i> , 2021, 11, 105-116.	0.8	5
36	Identifying Parkinson's disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering. <i>Scientific Reports</i> , 2021, 11, 23645.	1.6	11

#	ARTICLE	IF	CITATIONS
37	New evidence on the management of Lewy body dementia. <i>Lancet Neurology</i> , The, 2020, 19, 157-169.	4.9	167
38	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , The, 2020, 19, 71-80.	4.9	94
39	Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 32-36.	0.8	13
40	The Movement Disorder Society Nonmotor Rating Scale: Initial Validation Study. <i>Movement Disorders</i> , 2020, 35, 116-133.	2.2	59
41	Multimodal inÂvivo and postmortem assessments of tau in Lewy body disorders. <i>Neurobiology of Aging</i> , 2020, 96, 137-147.	1.5	14
42	0075 Neural Correlates of Cognitive Fatigue in Parkinson Disease. <i>Sleep</i> , 2020, 43, A30-A30.	0.6	0
43	Direct Medical Costs of Dementia With Lewy Bodies by Disease Complexity. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1696-1704.e5.	1.2	8
44	Clinical Followâ€p of Parkinson's Disease With Newly Prescribed Quetiapine. <i>Movement Disorders</i> , 2020, 35, 1690-1692.	2.2	0
45	ADNC-RS, a clinical-genetic risk score, predicts Alzheimerâ€™s pathology in autopsy-confirmed Parkinsonâ€™s disease and Dementia with Lewy bodies. <i>Acta Neuropathologica</i> , 2020, 140, 449-461.	3.9	7
46	Hallucinations and Development of Dementia in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1643-1648.	1.5	7
47	Tau pathology associates with in vivo cortical thinning in Lewy body disorders. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2342-2355.	1.7	20
48	Hippocampal subfield pathologic burden in Lewy body diseases <i>vs</i>. <i>Alzheimerâ€™s disease. Neuropathology and Applied Neurobiology</i> , 2020, 46, 707-721.	1.8	21
49	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. <i>Movement Disorders</i> , 2020, 35, 1999-2008.	2.2	104
50	Does a Positive Amyloid Scan Always Mean Alzheimer Disease?. , 2020, , 99-102.		0
51	I Donâ€™t Know When to Stop. , 2020, , 149-152.		0
52	Caring for the Caregiver. , 2020, , 155-157.		0
53	Cognitive Decline Is Only Part of the Story. , 2020, , 4-6.		0
54	Not Recognizing the Impostor. , 2020, , 64-66.		0

#	ARTICLE	IF	CITATIONS
55	Cognitive Impairment as an Unexpected Guest. , 2020, , 75-77.		0
56	“That Is Not How I Feel”, 2020, , 96-98.		0
57	Is Rapid Eye Movement Sleep Behavior Disorder a Risk Factor for Impulse Control Disorder in Parkinson Disease?. Annals of Neurology, 2020, 88, 759-770.	2.8	10
58	Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. Annals of Neurology, 2020, 88, 574-587.	2.8	55
59	Management of psychiatric disorders in Parkinson's disease. Neurotherapeutics, 2020, 17, 1511-1524.	2.1	19
60	Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?. Movement Disorders, 2020, 35, 1618-1625.	2.2	31
61	Factor Analysis and Clustering of the Movement Disorder Society“Non“Motor Rating Scale. Movement Disorders, 2020, 35, 969-975.	2.2	9
62	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross“Sectional Study. Movement Disorders, 2020, 35, 833-844.	2.2	48
63	Measurement properties from the Brazilian Portuguese version of the QUIP-RS. Npj Parkinson's Disease, 2020, 6, 6.	2.5	5
64	Impulse control and related behaviors in Parkinson“™s disease with dementia. European Journal of Neurology, 2020, 27, 944-950.	1.7	15
65	Frequency of and risk factors for potentially inappropriate medication use in Parkinson“™s disease. Age and Ageing, 2020, 49, 786-792.	0.7	9
66	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Annals of Clinical and Translational Neurology, 2020, 7, 449-461.	1.7	44
67	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. Annals of Neurology, 2019, 85, 259-271.	2.8	88
68	Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants. Movement Disorders Clinical Practice, 2019, 6, 440-445.	0.8	15
69	Longitudinal analyses of cerebrospinal fluid Î±“Synuclein in prodromal and early Parkinson's disease. Movement Disorders, 2019, 34, 1354-1364.	2.2	89
70	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. Movement Disorders, 2019, 34, 1839-1850.	2.2	122
71	Characterization of Parkinson“™s disease using blood-based biomarkers: A multicohort proteomic analysis. PLoS Medicine, 2019, 16, e1002931.	3.9	42
72	From action to abstraction: The sensorimotor grounding of metaphor in Parkinson's disease. Cortex, 2019, 121, 362-384.	1.1	12

#	ARTICLE	IF	CITATIONS
73	Genetic risk of Parkinson disease and progression. <i>Neurology: Genetics</i> , 2019, 5, e348.	0.9	109
74	Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. <i>Brain</i> , 2019, 142, 3592-3604.	3.7	90
75	Pilot Study of the International Parkinson and Movement Disorder Society'sponsored Non-motor Rating Scale (MDS-UOMS). <i>Movement Disorders Clinical Practice</i> , 2019, 6, 227-234.	0.8	31
76	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019, 62, 201-209.	1.1	15
77	Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2019, 402, 81-85.	0.3	6
78	Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2019, 34, 791-798.	2.2	49
79	Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. <i>Npj Parkinson's Disease</i> , 2019, 5, 7.	2.5	40
80	The Neuropsychiatry of Parkinson Disease: A Perfect Storm. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 998-1018.	0.6	82
81	Impulse control disorders in Parkinson's disease: A 20-year odyssey. <i>Movement Disorders</i> , 2019, 34, 447-452.	2.2	26
82	French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease'sRating Scale (QUIP-RS). <i>Parkinsonism and Related Disorders</i> , 2019, 63, 117-123.	1.1	9
83	Integration and Extension of Specialty Mental Healthcare Services to Community Practice in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 712-719.	0.6	13
84	TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia. <i>Annals of Neurology</i> , 2019, 85, 801-811.	2.8	52
85	Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2019, 69, 119-124.	1.1	26
86	Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2019, 5, 30.	2.5	32
87	Smaller subcortical volume in Parkinson patients with rapid eye movement sleep behavior disorder. <i>Brain Imaging and Behavior</i> , 2019, 13, 1352-1360.	1.1	20
88	Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease. <i>European Journal of Neurology</i> , 2019, 26, 246.	1.7	43
89	Impulse Control Disorders in Parkinson's Disease. <i>American Journal of Psychiatry</i> , 2019, 176, 5-11.	4.0	31
90	Pharmacological treatment of apathy in Lewy body disorders: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 14-24.	1.1	15

#	ARTICLE	IF	CITATIONS
91	Update on treatments for nonmotor symptoms of Parkinson's disease—“an evidence-based medicine review. <i>Movement Disorders</i> , 2019, 34, 180-198.	2.2	619
92	Risk of Parkinson's disease dementia related to level I MDS PD—MCI. <i>Movement Disorders</i> , 2019, 34, 430-435.	2.2	32
93	Elevated CSF GAP43 is Alzheimer's disease specific and associated with tau and amyloid pathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 55-64.	0.4	97
94	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. <i>JAMA Neurology</i> , 2019, 76, 318.	4.5	161
95	Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease. <i>JAMA Neurology</i> , 2019, 76, 41.	4.5	44
96	CSF tau and β -amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. <i>Neurology</i> , 2018, 90, e1038-e1046.	1.5	68
97	Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. <i>Movement Disorders</i> , 2018, 33, 499-500.	2.2	2
98	Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. <i>Movement Disorders</i> , 2018, 33, 771-782.	2.2	136
99	Quantitative assessment of finger tapping characteristics in mild cognitive impairment, Alzheimer's disease, and Parkinson's disease. <i>Journal of Neurology</i> , 2018, 265, 1365-1375.	1.8	73
100	Selection of Normative Group Affects Rates of Mild Cognitive Impairment in Parkinson's Disease. <i>Movement Disorders</i> , 2018, 33, 839-843.	2.2	12
101	At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 501-502.	2.2	1
102	Optimizing olfactory testing for the diagnosis of Parkinson's disease: item analysis of the university of Pennsylvania smell identification test. <i>Npj Parkinson's Disease</i> , 2018, 4, 2.	2.5	47
103	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. <i>Acta Neuropathologica</i> , 2018, 136, 363-376.	3.9	114
104	Initial cognitive changes in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 511-519.	2.2	41
105	Cerebrospinal fluid β -synuclein contributes to the differential diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1052-1062.	0.4	34
106	Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 78-88.	0.9	85
107	<i>APOE</i> , thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 289-297.	2.2	35
108	Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018, 33, 208-218.	2.2	138

#	ARTICLE	IF	CITATIONS
109	The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1460-1477.	1.7	330
110	Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1760-1768.	2.2	17
111	Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. <i>Movement Disorders</i> , 2018, 33, 1769-1776.	2.2	36
112	Detecting Mild Cognitive Deficits in Parkinson's Disease: A Comparison of Neuropsychological Tests. <i>Movement Disorders</i> , 2018, 33, 1750-1759.	2.2	42
113	Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018, 33, 450-457.	0.9	31
114	Cognition among individuals along a spectrum of increased risk for Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0201964.	1.1	33
115	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. <i>Brain</i> , 2018, 141, 2181-2193.	3.7	448
116	Prevalence of Impulsive-Compulsive Symptoms in Elderly Parkinson's Disease Patients. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	11
117	The Case for Antipsychotics in Dementia with Lewy Bodies. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 32-35.	0.8	20
118	The psychosis spectrum in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 81-95.	4.9	252
119	The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 39, 31-36.	1.1	37
120	Antipsychotic Use and Physical Morbidity in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 697-705.	0.6	28
121	The depressed brain in Parkinson's disease: Implications for an inflammatory biomarker. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3004-3005.	3.3	13
122	Cognitive decline in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 217-231.	4.9	705
123	Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease. <i>Neurobiology of Aging</i> , 2017, 56, 211.e1-211.e7.	1.5	37
124	Impulse Control Disorders and Related Complications of Parkinson's Disease Therapy. <i>Seminars in Neurology</i> , 2017, 37, 186-192.	0.5	25
125	Longitudinal decline in speech production in Parkinson's disease spectrum disorders. <i>Brain and Language</i> , 2017, 171, 42-51.	0.8	43
126	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.5	2,805

#	ARTICLE	IF	CITATIONS
127	Cognitive decline before diagnosis of Parkinson's disease – Authors' reply. <i>Lancet Neurology</i> , The, 2017, 16, 262.	4.9	2
128	Novel conformation-selective alpha-synuclein antibodies raised against different <i>in vitro</i> fibril forms show distinct patterns of Lewy pathology in Parkinson's disease. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 604-620.	1.8	51
129	Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis. <i>Journal of Parkinson's Disease</i> , 2017, 7, 385-395.	1.5	21
130	Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 787-795.	1.2	69
131	Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 325-331.	0.9	78
132	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. <i>Lancet Neurology</i> , The, 2017, 16, 55-65.	4.9	394
133	Cognition and the course of prodromal Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1640-1645.	2.2	39
134	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	2.2	608
135	Statins and Cognition in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 661-667.	1.5	13
136	Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 15-25.	1.7	40
137	Predictors of anxiety in early-stage Parkinson's disease – Results from the first two years of a prospective cohort study. <i>Parkinsonism and Related Disorders</i> , 2017, 43, 49-55.	1.1	30
138	Impulse Control and Related Disorders in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 679-717.	0.9	195
139	Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 66-75.	4.9	304
140	A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement. <i>Journal of Parkinson's Disease</i> , 2017, 7, 533-543.	1.5	45
141	Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 89.	3.0	129
142	Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders. <i>Frontiers in Human Neuroscience</i> , 2017, 10, 693.	1.0	1
143	Narrative Organization Deficit in Lewy Body Disorders Is Related to Alzheimer Pathology. <i>Frontiers in Neuroscience</i> , 2017, 11, 53.	1.4	7
144	Regional brain amyloid- β^2 accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. <i>PLoS ONE</i> , 2017, 12, e0177924.	1.1	33

#	ARTICLE	IF	CITATIONS
145	Parkinson's Disease Impulsive-Compulsive Disorders Questionnaire – Current Short (QUIP-CS) – Translation and validation of content of Portuguese Version. <i>Jornal Brasileiro De Psiquiatria</i> , 2017, 66, 111-115.	0.2	6
146	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. <i>PLoS ONE</i> , 2017, 12, e0175674.	1.1	110
147	Parkinson's disease-related fatigue: A case definition and recommendations for clinical research. <i>Movement Disorders</i> , 2016, 31, 625-631.	2.2	89
148	Memantine and Cognition in Parkinson's Disease Dementia/Dementia With Lewy Bodies: A Meta-Analysis. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 161-167.	0.8	12
149	Risperidone and Citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 784-792.	1.1	54
150	A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. <i>European Journal of Neurology</i> , 2016, 23, 1255-1261.	1.7	76
151	Plasma α -Synuclein and cognitive decline in Parkinson's disease and Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 346-355.	1.7	41
152	Development and Validation of the Parkinson's Disease Medication Beliefs Scale (PD-Rx). <i>Journal of Parkinson's Disease</i> , 2016, 6, 383-392.	1.5	7
153	Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1106-1111.	0.9	102
154	Hospital care for mental health and substance abuse conditions in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1810-1819.	2.2	14
155	Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 102-106.	1.1	99
156	The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 21-26.	1.1	42
157	Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. <i>American Journal of Psychiatry</i> , 2016, 173, 473-480.	4.0	63
158	Principal components analysis of agitation outcomes in Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2016, 79, 4-7.	1.5	4
159	High patient satisfaction with telehealth in Parkinson disease. <i>Neurology: Clinical Practice</i> , 2016, 6, 241-251.	0.8	83
160	Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. <i>European Journal of Neurology</i> , 2016, 23, 1556-1565.	1.7	51
161	Arguing against the proposed definition changes of PD. <i>Movement Disorders</i> , 2016, 31, 1619-1622.	2.2	55
162	The Danger of Not Treating Parkinson Disease Psychosis – Reply. <i>JAMA Neurology</i> , 2016, 73, 1156.	4.5	3

#	ARTICLE	IF	CITATIONS
163	Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire. <i>Movement Disorders</i> , 2016, 31, 126-134.	2.2	20
164	Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. <i>Movement Disorders</i> , 2016, 31, 86-94.	2.2	78
165	Association of <i>LRRK2</i> Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 1217.	4.5	185
166	Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 287-295.	1.2	77
167	Progress Regarding Parkinson's Disease Psychosis: It's No Illusion. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 431-434.	0.8	4
168	Fatigue in Parkinson's disease: report from a multidisciplinary symposium. <i>Npj Parkinson's Disease</i> , 2016, 2, .	2.5	61
169	Research consent capacity varies with executive function and memory in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 414-417.	2.2	12
170	Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2016, 74, 17-21.	1.5	41
171	Amyloid- β Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 367-375.	0.8	28
172	Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 270-279.	2.2	55
173	Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. <i>Movement Disorders</i> , 2016, 31, 709-714.	2.2	47
174	Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. <i>American Journal of Psychiatry</i> , 2016, 173, 465-472.	4.0	77
175	Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 535.	4.5	136
176	<i>LRRK2</i> Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 95-102.	2.2	158
177	CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. <i>Acta Neuropathologica</i> , 2016, 131, 935-949.	3.9	190
178	MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. <i>Journal of Neural Transmission</i> , 2016, 123, 431-438.	1.4	102
179	Olfactory impairment predicts cognitive decline in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 45-51.	1.1	97
180	A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 99-109.	0.8	14

#	ARTICLE	IF	CITATIONS
181	Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 864-870.	0.9	105
182	CSF β -Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease. <i>Journal of Molecular Neuroscience</i> , 2016, 58, 88-92.	1.1	89
183	Citalopram for the Treatment of Agitation in Alzheimer Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 59-64.	1.2	8
184	An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia. <i>PLoS ONE</i> , 2016, 11, e0147319.	1.1	25
185	Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. <i>International Psychogeriatrics</i> , 2015, 27, 2059-2067.	0.6	22
186	Efficacy of rasagiline in patients with Parkinson's disease and mild cognitive impairment: results from moderato, a 24-week randomized, double-blind, placebo-controlled trial. <i>Journal of the Neurological Sciences</i> , 2015, 357, e262.	0.3	0
187	Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 783-792.	1.5	37
188	Olfactory dysfunction in Parkinson's disease: Positive effect of cigarette smoking. <i>Movement Disorders</i> , 2015, 30, 859-862.	2.2	31
189	Advances in the treatment of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1471-1489.	2.2	65
190	Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 127-134.	0.8	20
191	Reply to letter to the editor "Independent application of MoCA/MMSE conversion" by Armstrong et al.. <i>Movement Disorders</i> , 2015, 30, 1711-1711.	2.2	0
192	Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo-controlled study. <i>Movement Disorders</i> , 2015, 30, 912-918.	2.2	91
193	Treatment changes among older patients with dementia treated with antipsychotics. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 1238-1249.	1.3	2
194	Cognitive profile of LRRK2-related Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 728-733.	2.2	64
195	Is the Parkinson anxiety scale comparable across raters?. <i>Movement Disorders</i> , 2015, 30, 545-551.	2.2	7
196	Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 688-695.	2.2	83
197	Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study. <i>JAMA Neurology</i> , 2015, 72, 88.	4.5	91
198	Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 629-634.	1.1	166

#	ARTICLE	IF	CITATIONS
199	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 919-927.	2.2	244
200	Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. <i>Lancet Neurology</i> , The, 2015, 14, 1002-1009.	4.9	179
201	Naltrexone for impulse control disorders in Parkinson disease: A placebo-controlled study. <i>Neurology</i> , 2015, 84, 1386-1387.	1.5	8
202	Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 1127-1133.	0.6	22
203	Longitudinal study of normal cognition in Parkinson disease. <i>Neurology</i> , 2015, 85, 1276-1282.	1.5	197
204	Caregiver report of apathy predicts dementia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 992-995.	1.1	29
205	Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype. <i>Movement Disorders</i> , 2015, 30, 805-812.	2.2	37
206	Clinical spectrum of impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 121-127.	2.2	264
207	Changes in QTc Interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) Randomized Trial. <i>PLoS ONE</i> , 2014, 9, e98426.	1.1	48
208	Effect of Citalopram on Agitation in Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 682.	3.8	447
209	Benefit finding and relationship quality in Parkinson's disease: A pilot dyadic analysis of husbands and wives.. <i>Journal of Family Psychology</i> , 2014, 28, 728-734.	1.0	30
210	People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. <i>Movement Disorders</i> , 2014, 29, 1258-1264.	2.2	76
211	Introduction: The importance of cognition in movement disorders. <i>Movement Disorders</i> , 2014, 29, 581-583.	2.2	7
212	Cognition in movement disorders: Where can we hope to be in ten years?. <i>Movement Disorders</i> , 2014, 29, 704-711.	2.2	15
213	Naltrexone for impulse control disorders in Parkinson disease. <i>Neurology</i> , 2014, 83, 826-833.	1.5	74
214	Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale-2 scores in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1809-1815.	2.2	86
215	<i>APOE</i> , <i>MAPT</i> , and <i>SNCA</i> Genes and Cognitive Performance in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 1405.	4.5	172
216	Course of psychiatric symptoms and global cognition in early Parkinson disease. <i>Neurology</i> , 2014, 83, 1096-1103.	1.5	116

#	ARTICLE	IF	CITATIONS
217	Understanding Psychosis in Parkinson's Disease. American Journal of Geriatric Psychiatry, 2014, 22, S35-S36.	0.6	0
218	Psychiatric issues in cognitive impairment. Movement Disorders, 2014, 29, 651-662.	2.2	41
219	Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODMSA) study group. Movement Disorders, 2014, 29, 857-867.	2.2	193
220	Anxiety Has Specific Syndromal Profiles in Parkinson Disease: A Data-Driven Approach. American Journal of Geriatric Psychiatry, 2014, 22, 1410-1417.	0.6	32
221	Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP) and the QUIP-rating scale in a German speaking sample. Journal of Neurology, 2014, 261, 936-942.	1.8	46
222	The Parkinson Anxiety Scale (PAS): Development and validation of a new anxiety scale. Movement Disorders, 2014, 29, 1035-1043.	2.2	173
223	Impulsive and compulsive behaviors among Danish patients with Parkinson's disease: Prevalence, depression, and personality. Parkinsonism and Related Disorders, 2014, 20, 22-26.	1.1	92
224	Is Sertraline Treatment or Depression Remission in Depressed Alzheimer Patients Associated with Improved Caregiver Well Being? Depression in Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry, 2014, 22, 14-24.	0.6	6
225	Initial cognitive decline is associated with cortical thinning in early Parkinson disease. Neurology, 2014, 82, 2017-2025.	1.5	158
226	Impulse control and related disorders in Mexican Parkinson's disease patients. Parkinsonism and Related Disorders, 2014, 20, 907-910.	1.1	39
227	Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable. Journal of Parkinson's Disease, 2014, 4, 585-589.	1.5	15
228	Task force report: Scales for screening and evaluating tremor: Critique and recommendations. Movement Disorders, 2013, 28, 1793-1800.	2.2	124
229	Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1113-1118.	0.9	130
230	APOE ϵ 4 Increases Risk for Dementia in Pure Synucleinopathies. JAMA Neurology, 2013, 70, 223.	4.5	302
231	The Diagnosis and Longitudinal Course of Common Movement Disorders in Geriatric Psychiatry. American Journal of Geriatric Psychiatry, 2013, 21, S34-S35.	0.6	0
232	Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?. Movement Disorders, 2013, 28, 1915-1919.	2.2	28
233	Neuropsychologic assessment in collaborative Parkinson's disease research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington. Alzheimer's and Dementia, 2013, 9, 609-614.	0.4	24
234	Neuropsychiatric Symptoms in Parkinson Disease and Dementia with Lewy Bodies: What Geriatric Psychiatry Can Learn. American Journal of Geriatric Psychiatry, 2013, 21, 497-500.	0.6	5

#	ARTICLE	IF	CITATIONS
235	Impulse Control and Related Disorders in Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2013, 11, 63-71.	0.8	82
236	Designing a new scale to measure anxiety symptoms in Parkinson's disease: item selection based on canonical correlation analysis. <i>European Journal of Neurology</i> , 2013, 20, 1198-1203.	1.7	17
237	Screening for impulse control symptoms in patients with de novo Parkinson disease: A case-control study. <i>Neurology</i> , 2013, 81, 694-695.	1.5	2
238	Screening for impulse control symptoms in patients with de novo Parkinson disease. <i>Neurology</i> , 2013, 80, 176-180.	1.5	194
239	Cognitive impairment and PD patients' capacity to consent to research. <i>Neurology</i> , 2013, 81, 801-807.	1.5	71
240	Impulse control disorders and related behaviors. , 2013, , 140-152.		3
241	Neuropsychiatric aspects of the on/off phenomenon. , 2013, , 275-284.		1
242	Glad about SAD (PD). <i>Neurology</i> , 2012, 78, 1198-1199.	1.5	6
243	Citalopram for agitation in Alzheimer's disease: Design and methods. <i>Alzheimer's and Dementia</i> , 2012, 8, 121-130.	0.4	45
244	Cognitive Outcomes After Sertaline Treatment in Patients With Depression of Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 1036-1044.	0.6	41
245	Medication Management and Neuropsychological Performance in Parkinson's Disease. <i>Clinical Neuropsychologist</i> , 2012, 26, 45-58.	1.5	31
246	Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. <i>Brain</i> , 2012, 135, 170-180.	3.7	149
247	Psychosis in Parkinson's disease without dementia: Common and comorbid with other non-motor symptoms. <i>Movement Disorders</i> , 2012, 27, 858-863.	2.2	109
248	Is depression in Parkinson's Disease (PD) a specific entity?. <i>Journal of Affective Disorders</i> , 2012, 139, 103-112.	2.0	34
249	Questionnaire for impulsive-compulsive disorders in Parkinson's Disease "Rating Scale. <i>Movement Disorders</i> , 2012, 27, 242-247.	2.2	263
250	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012, 27, 349-356.	2.2	1,908
251	Genetic influences on cognitive decline in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 512-518.	2.2	127
252	Sertraline for the Treatment of Depression in Alzheimer Disease: Genetic Influences. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2011, 24, 222-228.	1.2	14

#	ARTICLE	IF	CITATIONS
253	Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: Validity and variability. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 153-155.	1.1	61
254	Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis. <i>Archives of Neurology</i> , 2011, 68, 899.	4.9	105
255	A failure to communicate: Preliminary evidence for cortico-striatal dysconnection with pathological gambling in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 193-194.	2.2	0
256	Parkinson's disease: The quintessential neuropsychiatric disorder. <i>Movement Disorders</i> , 2011, 26, 1022-1031.	2.2	349
257	Both the body and brain benefit from exercise: Potential win-win for Parkinson's disease patients. <i>Movement Disorders</i> , 2011, 26, 607-607.	2.2	3
258	Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2051-2057.	2.2	67
259	MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD-MCI. <i>Movement Disorders</i> , 2011, 26, 1814-1824.	2.2	649
260	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, S42-80.	2.2	863
261	Cognitive impairment in nondemented Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2483-2495.	2.2	115
262	Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. <i>Annals of Neurology</i> , 2011, 69, 655-663.	2.8	126
263	Impulse control disorders in parkinson disease: A multicenter case-control study. <i>Annals of Neurology</i> , 2011, 69, 986-996.	2.8	361
264	Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study Å± 2 (DIADS-2)? <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 573-583.	1.3	49
265	Neurodegeneration Across Stages of Cognitive Decline in Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 1562.	4.9	180
266	Rivastigmine in Alzheimer's Disease and Parkinson's Disease Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2011, 26, 443-449.	0.9	37
267	Clinical Vignettes in Parkinson's Disease: A Collection of Unusual Medication-Induced Hallucinations, Delusions, and Compulsive Behaviours. <i>International Journal of Neuroscience</i> , 2011, 121, 472-476.	0.8	6
268	Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2010, 9, 573-580.	4.9	476
269	Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. <i>Annals of Neurology</i> , 2010, 68, 963-968.	2.8	132
270	Association between cognition and function in patients with Parkinson disease with and without dementia. <i>Movement Disorders</i> , 2010, 25, 1170-1176.	2.2	131

#	ARTICLE	IF	CITATIONS
271	Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1660-1669.	2.2	138
272	Case for and against specificity of depression in Alzheimer's disease. <i>Psychiatry and Clinical Neurosciences</i> , 2010, 64, 358-366.	1.0	18
273	Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. <i>Neurology</i> , 2010, 75, 448-455.	1.5	219
274	VALIDITY OF THE MoCA AND MMSE IN THE DETECTION OF MCI AND DEMENTIA IN PARKINSON DISEASE. <i>Neurology</i> , 2010, 75, 478-479.	1.5	39
275	Mild cognitive impairment in Parkinson disease. <i>Neurology</i> , 2010, 75, 1062-1069.	1.5	643
276	Impulse Control Disorders in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 589-95.	4.9	1,244
277	CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. <i>Neurology</i> , 2010, 75, 1055-1061.	1.5	315
278	Psychiatric Issues in Parkinson's Disease. <i>Blue Books of Neurology</i> , 2010, 34, 213-228.	0.1	3
279	Sertraline for the Treatment of Depression in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 136-145.	0.6	199
280	Sertraline for the Treatment of Depression in Alzheimer Disease: Week-24 Outcomes. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 332-340.	0.6	151
281	Treatment of Early Parkinson's Disease. <i>European Neurology</i> , 2009, 61, 193-205.	0.6	11
282	Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. <i>Neurology</i> , 2009, 73, 1738-1745.	1.5	946
283	Treatment of Early Parkinson's Disease. <i>European Neurology</i> , 2009, 61, 206-215.	0.6	12
284	Impulsive and compulsive behaviors in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1561-1570.	2.2	192
285	Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1461-1467.	2.2	394
286	The course of depressive symptoms in early Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1306-1311.	2.2	43
287	Montreal Cognitive Assessment Performance in Patients with Parkinson's Disease with "Normal" Global Cognition According to Mini-Mental State Examination Score. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 304-308.	1.3	270
288	Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 226-231.	1.1	163

#	ARTICLE	IF	CITATIONS
289	Involuntary emotional expression disorder (IEED) in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 511-515.	1.1	16
290	Pattern of Depressive Symptoms in Parkinson's Disease. <i>Psychosomatics</i> , 2009, 50, 448-454.	2.5	20
291	Impulse control disorders in Parkinson's disease: prevalence and possible risk factors. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S110-S113.	1.1	75
292	Use of Latent Variable Modeling to Delineate Psychiatric and Cognitive Profiles in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 986-995.	0.6	23
293	Frequency and Correlates of Involuntary Emotional Expression Disorder in Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2009, 21, 406-412.	0.9	20
294	Pattern of Depressive Symptoms in Parkinson's Disease. <i>Psychosomatics</i> , 2009, 50, 448-454.	2.5	6
295	Long-term follow-up of impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 75-80.	2.2	213
296	Suicidal and death ideation in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1573-1579.	2.2	106
297	Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2008, 23, 2004-2014.	2.2	285
298	Anxiety rating scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2008, 23, 2015-2025.	2.2	208
299	Diagnosis and management of Parkinson's disease dementia. <i>International Journal of Clinical Practice</i> , 2008, 62, 1581-1587.	0.8	77
300	Attitudes Regarding the Etiology and Treatment of Depression in Parkinson's Disease: A Qualitative Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2008, 21, 123-132.	1.2	44
301	Drs. Weintraub and Hurtig Reply. <i>American Journal of Psychiatry</i> , 2008, 165, 261-261.	4.0	0
302	Dopamine and impulse control disorders in Parkinson's disease. <i>Annals of Neurology</i> , 2008, 64, S93-S100.	2.8	120
303	Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. <i>American Journal of Managed Care</i> , 2008, 14, S40-8.	0.8	127
304	Intervening in the neuropsychiatric features of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 699-710.	1.4	6
305	Comparison and predictors of rash associated with 15 antiepileptic drugs. <i>Neurology</i> , 2007, 68, 1701-1709.	1.5	228
306	The impact of depressive symptoms in early Parkinson disease. <i>Neurology</i> , 2007, 69, 342-347.	1.5	278

#	ARTICLE	IF	CITATIONS
307	Presentation and Management of Psychosis in Parkinson's Disease and Dementia With Lewy Bodies. American Journal of Psychiatry, 2007, 164, 1491-1498.	4.0	102
308	Antidepressant Treatment of Veterans With Parkinson's Disease and Depression: Analysis of a National Sample. Journal of Geriatric Psychiatry and Neurology, 2007, 20, 161-165.	1.2	46
309	Phenylthiocarbamide (PTC) Perception in Parkinson Disease. Cognitive and Behavioral Neurology, 2007, 20, 145-148.	0.5	21
310	Disorders of mood and affect in Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 421-433.	1.0	4
311	Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease. Nature Clinical Practice Neurology, 2007, 3, 664-672.	2.7	84
312	Depression in veterans with Parkinson's disease: frequency, co-morbidity, and healthcare utilization. International Journal of Geriatric Psychiatry, 2007, 22, 543-548.	1.3	26
313	Differences in depression symptoms in patients with Alzheimer's and Parkinson's diseases: evidence from the 15-item Geriatric Depression Scale (GDS-15). International Journal of Geriatric Psychiatry, 2007, 22, 1025-1030.	1.3	27
314	Depression rating scales in Parkinson's disease: Critique and recommendations. Movement Disorders, 2007, 22, 1077-1092.	2.2	583
315	Effect of age on geriatric depression scale performance in Parkinson's disease. Movement Disorders, 2007, 22, 1331-1335.	2.2	62
316	Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease. New England Journal of Medicine, 2006, 355, 1525-1538.	13.9	1,067
317	Test Characteristics of the 15-Item Geriatric Depression Scale and Hamilton Depression Rating Scale in Parkinson Disease. American Journal of Geriatric Psychiatry, 2006, 14, 169-175.	0.6	205
318	Daily Affect in Parkinson Disease Is Responsive to Life Events and Motor Symptoms. American Journal of Geriatric Psychiatry, 2006, 14, 161-168.	0.6	17
319	Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease. Parkinsonism and Related Disorders, 2006, 12, 427-431.	1.1	37
320	Escitalopram for Major Depression in Parkinson's Disease: An Open-Label, Flexible-Dosage Study. Journal of Neuropsychiatry and Clinical Neurosciences, 2006, 18, 377-383.	0.9	35
321	Defining and Diagnosing Involuntary Emotional Expression Disorder. CNS Spectrums, 2006, 11, 1-11.	0.7	168
322	Impulse control disorders in parkinson's disease. Current Neurology and Neuroscience Reports, 2006, 6, 302-306.	2.0	66
323	Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease. Archives of Neurology, 2006, 63, 969.	4.9	601
324	Antidepressant studies in Parkinson's disease: A review and meta-analysis. Movement Disorders, 2005, 20, 1161-1169.	2.2	177

#	ARTICLE	IF	CITATIONS
325	Dimensions of Executive Function in Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 20, 140-144.	0.7	83
326	Therapeutic options for emotional lability: Current and emerging treatments. <i>American Journal of Geriatric Pharmacotherapy</i> , 2005, 3, 12-15.	3.0	2
327	[99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. <i>Neurology</i> , 2005, 64, 1716-1720.	1.5	150
328	Psychiatric Complications in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 844-851.	0.6	105
329	Pharmacologic Interventions for Psychosis and Agitation in Neurodegenerative Diseases: Evidence About Efficacy and Safety. <i>Psychiatric Clinics of North America</i> , 2005, 28, 941-983.	0.7	12
330	Electroconvulsive therapy for depression in a Parkinson's disease patient with bilateral subthalamic nucleus deep brain stimulators. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 403-406.	1.1	34
331	Psychiatric Complications in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 844-851.	0.6	68
332	Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. <i>Journal of Nuclear Medicine</i> , 2005, 46, 227-32.	2.8	164
333	Effect of Psychiatric and Other Nonmotor Symptoms on Disability in Parkinson's Disease. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 784-788.	1.3	333
334	Diagnosing and Treating Depression in Patients With Parkinson's Disease. <i>Psychiatric Annals</i> , 2004, 34, 298-304.	0.1	3
335	Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. <i>Cognitive and Behavioral Neurology</i> , 2004, 17, 195-200.	0.5	84
336	Pharmacologic Management of Psychosis in the Elderly: A Critical Review. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2003, 16, 213-218.	1.2	10
337	Recognition and Treatment of Depression in Parkinson's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2003, 16, 178-183.	1.2	177
338	Effect of Increasing the Dose and Duration of Sertraline Trial in the Treatment of Depressed Nursing Home Residents. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2003, 16, 109-111.	1.2	10
339	Probing the Safety of Medications in the Frail Elderly. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 875-882.	1.1	95
340	Change in the Rate of Restraint Use and Falls on a Psychogeriatric Inpatient Unit: Impact of the Health Care Financing Administration's New Restraint and Seclusion Standards for Hospitals. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2002, 15, 91-94.	1.2	6
341	Second-Generation Issues in the Management of Depression in Nursing Homes. <i>Journal of the American Geriatrics Society</i> , 2002, 50, 2100-2101.	1.3	9
342	Delirious mania in the elderly. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 374-377.	1.3	13

#	ARTICLE	IF	CITATIONS
343	Nortriptyline toxicity secondary to interaction with bupropion sustained-release. <i>Depression and Anxiety</i> , 2001, 13, 50-52.	2.0	17
344	Nortriptyline in Geriatric Depression Resistant to Serotonin Reuptake Inhibitors: Case Series. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2001, 14, 28-32.	1.2	10
345	Psychiatric Assessment of a Nursing Home Population Using Audiovisual Telecommunication. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2001, 14, 63-65.	1.2	37
346	The 36-Hour Day (3rd Edition). <i>American Journal of Geriatric Psychiatry</i> , 2001, 9, 179-179.	0.6	0
347	Amphetamine positive toxicology screen secondary to bupropion. <i>Depression and Anxiety</i> , 2000, 12, 53-54.	2.0	22
348	Clinical and demographic changes over ten years on a psychogeriatric inpatient unit. <i>Annals of Clinical Psychiatry</i> , 2000, 12, 227-231.	0.6	1
349	Residents in Personal Psychotherapy. <i>Academic Psychiatry</i> , 1999, 23, 14-19.	0.4	12
350	Electroconvulsive Therapy for Epilepsy and Major Depression. <i>American Journal of Geriatric Psychiatry</i> , 1998, 6, 180-183.	0.6	27
351	The boundaries of Parkinson's disease dementia and dementia with Lewy bodies. , 0, , 40-52.		0
352	Clinical assessment: mood and motivation. , 0, , 65-72.		0
353	Diagnosis and biomarkers: CSF. , 0, , 97-108.		0
354	Apathy. , 0, , 131-139.		0
355	Early cognitive impairment. , 0, , 163-176.		1
356	Parkinson's disease dementia. , 0, , 177-191.		0
357	Sleep disturbances. , 0, , 192-210.		0
358	Lessons and challenges of trials for cognitive and behavioral complications of Parkinson's disease. , 0, , 325-336.		0